Concepedia

Author

Thomas Chittenden

ImmunoGen (United States)ORCID

Also Known As

T. Chittenden, Thomas Chittenden, Thomas D. Chittenden

60

Publications

4.4K

Citations

13

H-Index

18

Concepts

All Affiliations

ImmunoGen (United States)Stanford University
TC

About

Thomas Chittenden is an author at ImmunoGen (United States) specializing in medicine, cell biology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

2.9K

2

Cell Biology

4

4

2.9K

3

Immunology

3

3

1.1K

4

Pathology

2

2

834

5

Cancer Cell Biology

1

1

309

Thomas Chittenden

×

12

Publications

4.2K

Citations

12

H-Index

YearCitations

p53 Has a Direct Apoptogenic Role at the Mitochondria

Motohiro Mihara, Susan Erster, Alexander Zaika,

Molecular Cell

2003

1.8K

Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen

Yelena Kovtun, Charlene A. Audette, Yumei Ye,

Cancer Research

2006

466

A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2

Victor S. Goldmacher, Laura M. Bartle, Anna Skaletskaya,

Proceedings of the National Academy of Sciences

1999

418

A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation

Anna Skaletskaya, Laura M. Bartle, Thomas Chittenden,

Proceedings of the National Academy of Sciences

2001

416

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle,

Clinical Cancer Research

2014

321

An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.

Erin K. Maloney, Jennifer L McLaughlin, Nancy E Dagdigian,

PubMed

2003

309

IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors

Olga Ab, Kathleen R. Whiteman, Laura M. Bartle,

Molecular Cancer Therapeutics

2015

209

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells

Yelena Kovtun, Gregory E. Jones, Sharlene Adams,

Blood Advances

2018

174

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies

Jutta Deckert, Peter U. Park, Sharon Chicklas,

Blood

2013

92

Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors

Juniper A. Scribner, Stuart W. Hicks, Kerstin W. Sinkevicius,

Molecular Cancer Therapeutics

2022

21

Page 1